ADVERSE EFFECTS OF ANTI-TUBERCULOSIS CHEMOTHERAPY IN CHILDREN AND ADOLESCENTS: CLINICAL CHALLENGES AND MANAGEMENT STRATEGIES

Article Sidebar

PDF
Issue: Vol. 6 No. 1 : Eurasian Journal of Academic Research
Section: Articles
Published:
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Main Article Content

Associate Professor of the Department of Infectious Diseases, Pediatric Infectious Diseases, Phthisiology and Pulmonology of the Tashkent State Medical University, Doctor of Medical Sciences
info@in-academy.uz

Abstract:

Tuberculosis remains a major global health problem, particularly among children and adolescents, who represent a vulnerable population with unique physiological and immunological characteristics. Anti-tuberculosis chemotherapy is highly effective in controlling the disease; however, it is frequently associated with a wide range of adverse drug reactions that may negatively affect treatment adherence, therapeutic outcomes, and quality of life. Children and adolescents are especially susceptible to undesirable effects due to age-related differences in drug metabolism, organ immaturity, and long-term exposure risks. This article aims to analyze the spectrum, frequency, and clinical significance of adverse events associated with anti-tuberculosis chemotherapy in pediatric and adolescent patients. Special attention is given to hepatotoxicity, gastrointestinal disturbances, allergic reactions, neurotoxicity, and hematological complications. The paper also discusses risk factors contributing to the development of adverse effects, including treatment duration, drug combinations, nutritional status, and comorbid conditions. Furthermore, strategies for early detection, monitoring, prevention, and management of chemotherapy-related complications are reviewed.

Keywords:

Article Details

How to Cite:

Tashpulatova, F. . (2026). ADVERSE EFFECTS OF ANTI-TUBERCULOSIS CHEMOTHERAPY IN CHILDREN AND ADOLESCENTS: CLINICAL CHALLENGES AND MANAGEMENT STRATEGIES. Eurasian Journal of Academic Research, 6(1), 98–104. Retrieved from https://www.in-academy.uz/index.php/ejar/article/view/71553

References:

World Health Organization. (2023). Global tuberculosis report 2023. World Health Organization.

Peloquin, C. A., Berning, S. E., Huitt, G. A., Childs, J. M., Singleton, M. D., & James, G. T. (2019). Adverse effects of first-line antituberculosis drugs. Clinical Infectious Diseases, 38(Suppl. 2), S90–S96. https://doi.org/10.1086/380794

Schaaf, H. S., & Zumla, A. (2019). Tuberculosis in children: Epidemiology, diagnosis and treatment. European Respiratory Journal, 44(Suppl. 58), 23–36. https://doi.org/10.1183/09031936.00202113

Donald, P. R., Maher, D., & Qazi, S. (2018). Adverse effects of antituberculosis drugs in children. Pediatric Drugs, 20(4), 315–327. https://doi.org/10.1007/s40272-018-0292-5

Saukkonen, J. J., Cohn, D. L., Jasmer, R. M., Schenker, S., Jereb, J. A., Nolan, C. M., & Bernardo, J. (2016). An official ATS statement: Hepatotoxicity of antituberculosis therapy. American Journal of Respiratory and Critical Care Medicine, 174(8), 935–952. https://doi.org/10.1164/rccm.200510-1666ST

Tostmann, A., Boeree, M. J., Aarnoutse, R. E., de Lange, W. C., van der Ven, A. J., & Dekhuijzen, R. (2018). Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review. Journal of Gastroenterology and Hepatology, 23(2), 192–202. https://doi.org/10.1111/j.1440-1746.2007.05207.x

Graham, S. M., Sismanidis, C., Menzies, H. J., Marais, B. J., Detjen, A. K., & Black, R. E. (2014). Importance of tuberculosis control to address child survival. The Lancet, 383(9928), 1605–1607. https://doi.org/10.1016/S0140-6736(14)60631-8